Navigation Links
Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
Date:4/21/2008

e patients," he added.

The approval was based on one-year follow-up data from the first 194 HeartMate II BTT patients enrolled in the trial. Highlights of the data included in the final PMA submission included:

-- The median duration of support was 132 days, and the cumulative

patient support in the trial was 109 years.

-- Survival to cardiac transplantation, recovery or ongoing on HeartMate

II support was 80 percent at six months and 77 percent at one year.

-- Eighty four percent of the patients survived to hospital discharge or

transplantation.

-- Significant improvements were observed across all measures of

functional status and quality of life as compared to baseline status.

-- The incidence of major adverse events with comparable

definitions -- including infections, strokes and bleeding requiring

surgery -- was significantly lower than what was clinically observed

in the previous BTT study of the HeartMate VE LVAS.

The approval allows the HeartMate II to be used to treat small patients (BSA < 1.5) based on body habitus if the treating clinician believes that the patient could benefit from the device. In addition, Thoratec will conduct a post-market study that includes a concurrent comparator. The study will follow 169 HeartMate II patients until outcome, or one year -- whichever comes first -- and gather data regarding survival, adverse events, patient gender, small patients and anticoagulation levels.

"With this BTT approval, we will now initiate our sales and marketing programs designed to place the HeartMate II in transplant centers that did not participate in the clinical trial. Our hope is to add about 40 new centers during the balance of the year, which would bring the total number of centers implanting the HeartMate II to approximately 80 centers.

"The foundation of this effort is a strong training program and supp
'/>"/>

SOURCE Thoratec Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
2. Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein
3. Genetic Immunity Announces Data Related to the DermaVir Nanomedicine Patch in the Journal of Immunology
4. InterMune Announces Progress on Pirfenidone in IPF
5. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
6. Aida Announces New Anti-Cancer Drug Under Development
7. AlphaVax Announces Initial Analysis of Data From CMV Phase 1 Clinical Trial
8. Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
9. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
10. ViroPharma Announces Discontinuation of HCV-796 Development
11. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , August 27, 2014 ... Market By Products (Dental Radiology, CAD/CAM, Dental Chairs, Dental Lasers), Current ... by MarketsandMarkets, the global Dental Equipment Market is expected ... million in 2014, growing at a CAGR of ... 95 market data tables and 61 figures spread ...
(Date:8/27/2014)... Aug. 27, 2014 Pulse Systems, Inc. , ... Practice Management , and Revenue Cycle Management (RCM) ... practices performed by some RCM vendors, at UBM Medica,s ... on September 19-20, 2014.  A presenter ... in September with a new session encouraging practices to "Look ...
(Date:8/27/2014)... 2014 Sihuan Pharmaceutical Holdings Group Ltd. ... leading pharmaceutical company with the largest cardio-cerebral vascular ... prescription drug market, today announced the unaudited ... (collectively the "Group") for the six months ended ... HighlightsFor the Six months ended 30 JuneKey Income ...
Breaking Medicine Technology:Dental Equipment Market Worth $7,138.9 Million by 2019 2Dental Equipment Market Worth $7,138.9 Million by 2019 3Pulse Systems Presents the Truth about Revenue Cycle Management Services at Practice Rx 2Pulse Systems Presents the Truth about Revenue Cycle Management Services at Practice Rx 3Pulse Systems Presents the Truth about Revenue Cycle Management Services at Practice Rx 4Sihuan Pharmaceutical Announces 2014 Interim Results 2Sihuan Pharmaceutical Announces 2014 Interim Results 3Sihuan Pharmaceutical Announces 2014 Interim Results 4Sihuan Pharmaceutical Announces 2014 Interim Results 5Sihuan Pharmaceutical Announces 2014 Interim Results 6Sihuan Pharmaceutical Announces 2014 Interim Results 7
(Date:8/27/2014)... WEDNESDAY, Aug. 27, 2014 (HealthDay News) -- A new ... an effective treatment for seniors with sleep apnea. ... obstructive sleep apnea, a condition in which the airway ... interrupted sleep that leads to daytime drowsiness. ... stream of air through a patient,s nose via a ...
(Date:8/27/2014)... from our parents shapes many aspects of our lives. ... epigenome that is set during development, but can be ... by those of our parents and grandparents. , The ... supporting proteins that determine whether genes are expressed or ... our own health, but also that it may be ...
(Date:8/27/2014)... Boston, MA (PRWEB) August 27, 2014 Tejal ... Patient Safety Foundation (NPSF) and the NPSF Lucian Leape ... announced in the August 25 issue of Modern Healthcare magazine. ... MD, PhD; and Andrew Sussman, MD, MBA; NPSF Lucian ... Gary Kaplan, MD, who is a member of both the ...
(Date:8/27/2014)... August 27, 2014 Scientists at The Scripps ... a specific signaling pathway can be associated with alcohol ... a gene, called neurofibromatosis type 1 (Nf1), which TSRI ... The new research shows Nf1 regulates gamma-aminobutyric acid (GABA), ... relaxation. , "This novel and seminal study provides ...
(Date:8/27/2014)... Georgia State University’s Center for Leadership in Disability ... the Maternal and Child Health Bureau of the ... of the Autism Plan for Georgia, aimed at ... spectrum disorder. , In preparing for this project, ... of key stakeholders from across Georgia. The resulting ...
Breaking Medicine News(10 mins):Health News:Sleep Apnea Treatment Helps Seniors, Study Finds 2Health News:Scientists map the 'editing marks' on fly, worm, human genomes 2Health News:Scientists map the 'editing marks' on fly, worm, human genomes 3Health News:Scientists map the 'editing marks' on fly, worm, human genomes 4Health News:NPSF President Among 100 Most Influential in Health Care 2Health News:NPSF President Among 100 Most Influential in Health Care 3Health News:Scripps Research Institute scientists link alcohol-dependence gene to neurotransmitter 2Health News:Center for Leadership in Disability Awarded $600,000 Grant to Improve Services for Georgia’s Children and Youth with Autism 2
... Adlyfe, a private company,developing novel diagnostic testing ... that it has appointed Roxanne Duan, Ph.D.,as Vice ... for overseeing,the Adlyfe,s Research efforts and will report ... to Adlyfe with nearly two decades of experience. ...
... 17 Symmetry Medical Inc.,(NYSE: SMA ), ... orthopedic,device industry and other medical markets, announced today ... http://www.symmetrymedical.com, which contains improved,user- friendly features. ... languages, provides easy to,find product information and a ...
... concludes, , , MONDAY, Sept. 17 (HealthDay News) -- ... asthma you develop, new research suggests. , The ... countries had more allergy-triggered asthma symptoms than did ... "The link between atopic sensitization and asthma symptoms ...
... YORK -- Before a new treatment becomes available, researchers ... in clinical research trials. But finding these patients is ... studies or unable to participate due do logistical hurdles. ... novel treatment approaches -- and beneficial new therapies take ...
... SAN DIEGO, Sept. 17 CryoCor, Inc. (Nasdaq:,CRYO), a ... announced today that Edward F. Brennan, President and Chief,Executive ... to present at the Maxim Group First Annual Growth ... at 10:00 a.m. ET at The Grand,Hyatt Hotel. ...
... address the nation,s largest public health challenges, including AIDS, should be ... ... plans, WASHINGTON, Sept. 17 ... next President to,commit to ending the AIDS epidemic in America. They ...
Cached Medicine News:Health News:Adlyfe Appoints Roxanne Duan as Vice President of Research 2Health News:Adlyfe Appoints Roxanne Duan as Vice President of Research 3Health News:Symmetry Medical Launches New Global Web site 2Health News:Symmetry Medical Launches New Global Web site 3Health News:Allergy-Induced Asthma More Common in Affluent Countries 2Health News:Allergy-Induced Asthma More Common in Affluent Countries 3Health News:IMPACT initiative looks to improve patient participation in clinical trials 2Health News:CryoCor to Present at Maxim Group First Annual Growth Conference in New York 2Health News:More Than 100 Organizations Call for a National AIDS Strategy to End the Epidemic in the United States 2Health News:More Than 100 Organizations Call for a National AIDS Strategy to End the Epidemic in the United States 3
... designed to give reliable performance for all mixing ... button, power supply socket and fuse holder are ... The speed knob is located on the bottom ... a minimum 950 rpm to a maximum of ...
ThermoPrep 3's two systems in "one" approach, its capability to accommodate up to two standard microplates and its user-selectable settings offers the versatility and throughput you need in today's l...
... only four-color, automated benchtop flow cytometry system ... sorting. Designed specifically to support a wide ... software instrument control, auto-sample loading, and push-button ... FACSCalibur is fully modular so it can ...
... cytometer especially suited for cell analysis ... CyFlow allows to analyze scatter signals ... fluorescence channels. Data acquisition, analysis, and ... built-in PC employing Partec DPAC software, ...
Medicine Products: